RECITALSConsent and Termination Agreement • December 12th, 2001 • Dj Orthopedics Capital Corp • Orthopedic, prosthetic & surgical appliances & supplies • Delaware
Contract Type FiledDecember 12th, 2001 Company Industry Jurisdiction
CONSENT AND TERMINATION AGREEMENTConsent and Termination Agreement • April 29th, 2004 • CDR Cookie Acquisition LLC • Services-computer programming services • New York
Contract Type FiledApril 29th, 2004 Company Industry JurisdictionTHIS CONSENT AND TERMINATION AGREEMENT (this “Agreement”) is made and entered into as of the 26th day of April, 2004, by and among Rajendra B. Vattikuti (“Vattikuti”), The Rajendra B. Vattikuti Trust, established pursuant to the Second Amendment and Restatement of Revocable Living Trust Agreement, dated as of February 1, 1995 (the “Vattikuti Trust” and, collectively with Vattikuti, the “Vattikuti Entities”), and CDR-Cookie Acquisition, L.L.C., a Delaware limited liability company (“CDR”).
CONSENT AND TERMINATION AGREEMENTConsent and Termination Agreement • January 4th, 2008 • Phoenix Footwear Group Inc • Footwear, (no rubber) • New York
Contract Type FiledJanuary 4th, 2008 Company Industry JurisdictionThis Consent and Termination Agreement is made as of December 29, 2007 by and among Manufacturers and Traders Trust Company (“Agent”), as Administrative Agent for the Lenders (“Lenders”) described in the Credit Agreement referenced below and Phoenix Footwear Group, Inc. (“Borrower”), and as sole Lender under the Credit Agreement.
CONSENT AND TERMINATION AGREEMENTConsent and Termination Agreement • April 30th, 2004 • Peregrine Systems Inc • Services-prepackaged software • California
Contract Type FiledApril 30th, 2004 Company Industry JurisdictionTHIS CONSENT AND TERMINATION AGREEMENT (this “Consent”) is dated as of August 7, 2003 and is made by and among Fleet Business Credit, LLC, a Delaware limited liability company (“Fleet”), Wells Fargo HSBC Trade Bank, N.A., a national banking association (the “Trade Bank”), Silicon Valley Bank, a California state bank (“SVB” and together with Fleet and Trade Bank, each a “Purchaser” and, collectively, the “Purchasers”), and Fleet, as agent for the Purchasers (“Purchaser Agent”).
CONSENT AND TERMINATION AGREEMENTConsent and Termination Agreement • September 13th, 2019 • Fibrocell Science, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledSeptember 13th, 2019 Company Industry JurisdictionTHIS CONSENT AND TERMINATION AGREEMENT (hereinafter referred to as this “Agreement”) is made and entered into as of September 12, 2019 by and among Castle Creek Pharmaceutical Holdings, Inc., a Delaware corporation (“Parent”), Fibrocell Science, Inc., a Delaware corporation (the “Company”), MSD Credit Opportunity Master Fund, L.P., a Cayman exempt limited partnership (the “Securityholder”), and Castle Creek Merger Corp., a Delaware corporation (“Merger Sub”).
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Consent and Termination AgreementConsent and Termination Agreement • May 2nd, 2024 • Blueprint Medicines Corp • Pharmaceutical preparations
Contract Type FiledMay 2nd, 2024 Company IndustryThis Consent and Termination Agreement (this “Termination Agreement”), dated February 22, 2024, is by and between Royalty Pharma Investments 2019 ICAV, an Irish collective-asset management vehicle (“Investor”), and Blueprint Medicines Corporation (“Company”). Reference is made to that certain Purchase and Sale Agreement, dated June 30, 2022, by and between Investor and Company (the “RPA”). Any capitalized term used but not defined in this Termination Agreement shall have the meaning ascribed to such term in the RPA.
CONSENT AND TERMINATION AGREEMENTConsent and Termination Agreement • September 13th, 2019 • Fibrocell Science, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledSeptember 13th, 2019 Company Industry JurisdictionTHIS CONSENT AND TERMINATION AGREEMENT (hereinafter referred to as this “Agreement”) is made and entered into as of September 12, 2019 by and among Castle Creek Pharmaceutical Holdings, Inc., a Delaware corporation (“Parent”), Fibrocell Science, Inc., a Delaware corporation (the “Company”), the undersigned securityholders of the Company (collectively the “Securityholders” and each individually, a “Securityholder”), and Castle Creek Merger Corp., a Delaware corporation (“Merger Sub”).